An Open-Label, Multicenter, Randomized Study Evaluating the Tolerability and Safety of Two Formulations of Glatiramer Acetate (GA) for Subcutaneous Injection.

Trial Profile

An Open-Label, Multicenter, Randomized Study Evaluating the Tolerability and Safety of Two Formulations of Glatiramer Acetate (GA) for Subcutaneous Injection.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Glatiramer acetate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms Song
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 13 Oct 2010 Results presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 08 Jun 2010 Results were presented at the 24th Annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC), according to a Teva Pharmaceuticals media release.
    • 03 May 2010 Actual end date (1 Nov 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top